Zynerba Pharmaceuticals, Inc.
ZYNEDelisted Oct 11, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001621443
Zynerba Pharmaceuticals, Inc. was delisted on Oct 11, 2023; its insiders filed their last Form 4 on Oct 11, 2023; 43 institutions reported holding it in 13F filings for Q3 2023, worth $14.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 43
- Q3 2023, +3 vs. previous quarter
- 13F value
- $14.7M
- Reported value at the end of Q3 2023
- Superinvestors holding
- 0
- At the end of Q3 2023
Superinvestors holding ZYNE, Q3 2023
No superinvestor reported holding ZYNE at the end of Q3 2023.
Latest insider trades
Open-market purchases and sales by Zynerba Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2023 (view filing) | Sep 13 | 1 day | Sebree Terri BPresident | SSale | −12.4K | $1.33 | −$16.5K | −2.0%596.2K after | |
| Sep 14, 2023 (view filing) | Sep 13 | 1 day | Rosenberger BrianVP, Commercial & Business Dev. | SSale | −6.41K | $1.33 | −$8.53K | −2.5%249.6K after | |
| Sep 14, 2023 (view filing) | Sep 13 | 1 day | Fickenscher James EChief Financial Officer | SSale | −9.00K | $1.33 | −$12.0K | −2.3%378.1K after | |
| Sep 14, 2023 (view filing) | Sep 13 | 1 day | Jones Kenneth TSee Remarks | SSale | −2.50K | $1.33 | −$3.33K | −2.8%85.5K after | |
| Sep 14, 2023 (view filing) | Sep 13 | 1 day | Anido ArmandoChairman & Chief Exec. Officer | SSale | −17.8K | $1.33 | −$23.7K | −1.9%936.7K after | |
| Jun 15, 2023 (view filing)4:30 PM ET | Jun 14 | 1 day | Stephenson PamelaDirector | SSale | −115 | $0.3481 | −$40.03 | −0.2%75.8K after | |
| Jun 15, 2023 (view filing)4:30 PM ET | Jun 14 | 1 day | Moch Kenneth IDirector | SSale | −115 | $0.3481 | −$40.03 | −0.2%75.8K after | |
| Jun 15, 2023 (view filing)4:29 PM ET | Jun 14 | 1 day | Kisner Daniel LDirector | SSale | −115 | $0.3481 | −$40.03 | −0.2%75.8K after | |
| Jun 15, 2023 (view filing)4:29 PM ET | Jun 14 | 1 day | Federici William JDirector | SSale | −115 | $0.3481 | −$40.03 | −0.2%75.8K after | |
| Jun 15, 2023 (view filing)4:28 PM ET | Jun 14 | 1 day | Butler John P.Director | SSale | −115 | $0.3481 | −$40.03 | −0.1%80.8K after |
Top 10 13F holders, Q3 2023
The largest institutional positions in Zynerba Pharmaceuticals, Inc. at the end of Q3 2023; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Beryl Capital Management LLC | 4,898,927 | $6.25M | 0.79% | +4,898,927 | New |
| Highbridge Capital Management LLC | 2,283,979 | $2.91M | 0.16% | +2,283,979 | New |
| Yakira Capital Management, Inc. | 620,019 | $790.5K | 0.21% | +620,019 | New |
| Renaissance Technologies LLC | 605,700 | $772.0K | 0.00% | −84,013−12.2% | Reduced |
| CSS LLC | 476,831 | $608.0K | 0.05% | +476,831 | New |
| Deltec Asset Management LLC | 475,000 | $605.6K | 0.14% | +475,000 | New |
| Millennium Management LLC | 325,237 | $413.1K | 0.00% | +199,402+158.5% | Added |
| Jane Street Group, LLC | 282,478 | $360.2K | 0.00% | +282,478 | New |
| Crystalline Management Inc. | 230,817 | $294.3K | 0.22% | +230,817 | New |
| Susquehanna International Group, LLP | 221,719 | $281.6K | 0.00% | +221,719 | New |